Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics (TRVI) has caught the attention of investors after recent updates on its chronic cough clinical programs. The company is moving ahead with Phase 3 plans for IPF-related chronic ...
Trevi Therapeutics (NASDAQ: TRVI) will release its quarterly earnings report on Thursday, 2025-11-13. Here's a brief overview ...
Discover key insights from Trevi Therapeutics' Q3 2025 earnings call, including clinical progress, strong financials, and upcoming regulatory milestones.
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Trevi Therapeutics (TRVI) to $19 from $18 and keeps an Overweight rating on ...
Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Trevi Therapeutics today and set a price target of $25.00. Meet Your ETF AI Analyst. Discover how TipRanks' ET ...
Patients with refractory chronic cough who received twice-daily Haduvio for 21 days had decreases in cough frequency and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback